Immatics N.v. · NASDAQ:IMTX
Immatics — Investor Presentation (January 2025)
45 slides from Immatics's investor presentation, Jan 13, 2025
Slide 1: Immatics Corporate Presentation
Delivering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation January 13, 2025
Slide 2: Forward-Looking Statement
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their resp
Slide 3: Commercializing PRAME cell therapy in 2L cutaneous melanoma
3 Commercializing PRAME cell therapy in 2L cutaneous melanoma Expanding the PRAME commercial opportunity to earlier lines and additional solid cancer types IMA203 expansion into uveal melanoma through ongoing Phase 1b trial IMA203CD8 GEN2 in PRAME+ solid cancers, starting with gynecologic cancers IM
Slide 4: Transformative pipeline of TCR-based therapies
4 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion; 2 mRNA - enabled in vivo expressed TCER® molecules; 3 Immatics’ proprietary ACTallo® platform utilizing Editas’ CRISPR gene editing technology 2L: patients with unresectable or metastatic melanoma who have received at least 1 prior therapy; HN
Slide 5: Immatics' Clinical Portfolio
Immatics’ Clinical Portfolio 5 Clinical Activity 1 Positioning Next Data Update Expanding the PRAME cell therapy opportunity to earlier lines and additional solid cancer types beyond melanoma Data updates on all clinical assets throughout 2025 4 Clinically Active TCR Candidates Across 2 Modalities C
Slide 6: Breadth of PRAME Commercial Opportunity in Solid Cancers
Breadth of PRAME Commercial Opportunity in Solid Cancers Based on Positive Data and High Unmet Need 6 ~230k addressable P RA M E + /HL A - A*02:0 1 + patients in the US & EU5 Near - Term Mid - & Long - Term 2L Unresectable or Metastatic Cut. Melanoma IMA203 BRAF WT or BRAF mutated 2L Unresectable or
Slide 7: Leadership in the Development of TCR-based Therapies
Leadership in the Development of TCR - based Therapies Two Distinct TCR - based Therapeutic Modalities in Clinical Development 7 I n t r o 1 Minimal target product profile (TPP) in monotherapy in 2L settings at recommended phase 2 dose (RP2D), i.e. typically in Ph1b dose expansion, for go - /no - go
Slide 8: ACTengine IMA203 – TCR-Based Cell Therapy Targeting PRAME
ACTengine® IMA203 – TCR - Based Cell Therapy Targeting PRAME 8
Slide 9: The ACTengine IMA203 Commercial Opportunity in 2L Melanoma
The ACTengine® IMA203 Commercial Opportunity in 2L Melanoma TCR - Based Cell Therapy Targeting PRAME 9 IMA203 Opportunity ~ 7.3 k ad d r e s s a ble PRAME + /HLA - A*02:01 + patients in the US & EU5 ~1.3k addressable P RA M E + /HLA - A*02:01 + patients in the US & EU5 All patient numbers refer to P
Slide 10: ACTengine IMA203 TCR-T Monotherapy Targeting PRAME in Melanoma
10 I MA2 0 3 Data cut - off Aug 23, 2024 SUPRAME Phase 3 trial in 2L melanoma commenced in December 2024 1 Includes all benefits of Breakthrough Therapy Designation; * PRAME + /HLA - A*02:01 + addressable patient population, source: Clarivate Disease Landscape and Forecast 2025; CRS: cytokine releas
Slide 11: ACTengine IMA203 TCR-T Monotherapy – Patient Flow
ACTengine® IMA203 TCR - T Monotherapy – Patient Flow 11 * 30 mg/m 2 Fludarabine and 500 mg/m 2 Cyclophosphamide for 4 days; ** 1m IU daily days 1 - 5 and twice daily days 6 - 10, total dose is approx. only 5% of the overall dose for high - dose IL - 2 given typic ally with TIL therapy (Sarnaik et al
Slide 12: ACTengine IMA203 TCR-T Trial in Melanoma
ACTengine® IMA203 TCR - T Trial in Melanoma Heavily Pretreated Patient Population Data cut - off Aug 23, 2024 12 1 All infused patients; *Cutaneous melanoma patients had a median of 2 prior lines of checkpoints, see appendix; RP2D: recommended phase 2 dose; CPI: Checkpoint inhibitors; EC1: 0.06 - 0.
Slide 13: Most Frequent Adverse Events of IMA203
13 Data cut - off Aug 23, 2024 * One grade 3 CRS only after exploratory second infusion; CRS and ICANS graded by CARTOX criteria (Neelapu et al ., 2019); ICANS: Immune effector cell - associated neurotoxicity syndrome Most Frequent Adverse Events of IMA203 Across All Dose Levels in Phase 1a/b N=70 P
Slide 14: Tolerability Profile of IMA203 Across All Dose Levels
Tolerability Profile of IMA203 Across All Dose Levels in Phase 1a/b All ≥Grade 3 Adverse Events (N=70 1 ) TEAEs by maximum severity for all patients in Phase 1a and Phase 1b (N=70 1 ) Data cut - off Aug 23, 2024 14 ≥ Grade 3 Adverse event ( System organ class , Preferred term) % No. 100.0 70 Patient
Slide 15: Clinical Anti-Tumor Activity of IMA203 Monotherapy in Melanoma
Clinical Anti - Tumor Activity of IMA203 Monotherapy in Melanoma Objective Responses in Heavily Pretreated Patients in Phase 1b (N=28 # ) Data cut - off Aug 23, 2024 15 ongoi n g # First tumor assessment post infusion pending for two melanoma patients at data - cut; * Maximum change of target lesion
Slide 16: Duration of IMA203 Monotherapy Responses in Melanoma
Duration of IMA203 Monotherapy Responses in Melanoma Durable Responses 2+ Years after Treatment in Heavily Pretreated Patients in Phase 1b (N=28 # ) 16 Ongoing Scans at approximately week 6, month 3 and then every 3 months Data cut - off Aug 23, 2024 # First tumor assessment post infusion pending fo
Slide 17: Significant Shift in PFS and OS Between Dose Escalation & Expansion
Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion mPFS of 6 Months and mOS Not Reached in Melanoma Efficacy Population Progression Free Survival Data cut - off Aug 23, 2024 17 Overall Survival Overall survival (OS) and progression - free survival (PFS) censored at data - cut;
Slide 18: IMA203 Phase 1b in Melanoma: Overview of Studies
IMA203 Phase 1b in Melanoma: Overview of Studies PFS and OS Data in Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies Melanoma patient population N Phase Drug Product not reached 6.0 4% n=0, 18% n=1, 32% n=2, 29% n=3:, 4% n=4, 11% n=5, 4% n=6 86% received prior CPI (median of 1 pr
Slide 19: Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses
Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses N=26 # 19 • 46% (12/26) patients have a deep response (≥50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase) sti
Slide 20: SUPRAME: Registration-Enabling Randomized Phase 3 Trial
SUPRAME: Registration - Enabling Randomized Phase 3 Trial Trial Design Following Recent Type D Meeting with FDA and SA Meeting with PEI 1 20 ACTengine® IMA203 N=180 Investigator’s choice of selected approved treatments N=180 Endpoints • Primary Endpoint • PFS, which allows trial readout quicker than
Slide 21: Cell Therapy Manufacturing Facility To Support IMA203 BLA and Commercialization
Cell Therapy Manufacturing Facility To Support IMA203 BLA and Commercialization 21 I MA2 0 3 • ~100,000 sq ft state - of - the - art research & GMP manufacturing facility • Modular design for efficient and cost - effective scalability - total of 8 manufacturing suites, plus further expansion space •
Slide 22: ACTengine IMA203CD8 Expansion of the PRAME Commercial Opportunity Beyond Melanoma
ACTengine® IMA203CD8 Expansion of the PRAME Commercial Opportunity Beyond Melanoma 22
Slide 23: Expansion of PRAME Commercial Opportunity Beyond Melanoma
Expansion of PRAME Commercial Opportunity Beyond Melanoma Second Generation ACTengine® IMA203CD8 Leveraging CD8 and CD4 T Cells 23 IMA203CD8 Opportunity 2L Solid Tumors All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and F
Slide 24: IMA203CD8 TCR-T Monotherapy Summary: Clinical Data & Next Steps
ACTengine® IMA203CD8 TCR - T Monotherapy Targeting PRAME Summary: Clinical Data & Next Steps Data cut - off Sep 30, 2024 24 Dose escalation ongoing to investigate full clinical potential in hard - to - treat solid tumors outside of melanoma IMA203CD8 Tolerability Manageable tolerability ≥Grade 3 AEs
Slide 25: Tolerability of IMA203CD8 Monotherapy
Tolerability of IMA203CD8 Monotherapy 25 All ≥Grade 3 Adverse Events (N=44) Data cut - off Sep 30, 2024 IMA203CD8 … table continued 100.0 44 Patients with any adverse event 9.1 4 Immune system disorders 15.9 7 Adverse events of special interest 9.1 4 Haemophagocytic lymphohistiocytosis 2 13.6 6 Cyto
Slide 26: Clinical Anti-Tumor Activity of IMA203CD8 Monotherapy
Clinical Anti - Tumor Activity of IMA203CD8 Monotherapy (N=41) Ongoing Dose Escalation Data cut - off Sep 30, 2024 26 IMA203CD8 41% (14/34) c O R R 9.2 months 2.0+, 23.5+ 13.1 months median DOR (min, max) m FU 10/17 responses ongoing including 3 confirmed responses at 1+ year Deep responses with ≥50
Slide 27: Duration of IMA203CD8 Monotherapy Responses
Duration of IMA203CD8 Monotherapy Responses (N=41) Ongoing Dose Escalation Data cut - off Sep 30, 2024 27 IMA203CD8 1 Metabolic complete response (CR) according to PET - CT 2 Patients off study at data - cut; 3 three patients excluded from tumor shrinkage analysis and figures due to lack of post - t
Slide 28: Opportunity of IMA203CD8 in Medium-Level PRAME Expressing Indications
Opportunity of IMA203CD8 in Medium - Level PRAME Expressing Indications 28 * Patients treated at RP2D during Ph1b with evaluable post baseline assessments at data - cut off IMA203: Aug 23, 2024; BOR: best of response; PD: progressive disease; SD: stable disease; (c)PR: (confirmed) partial response;
Slide 29: TCER IMA402 - Off-the-Shelf TCR Bispecific Targeting PRAME
TCER® IMA402 - Off - the - Shelf TCR Bispecific Targeting PRAME 29
Slide 30: IMA402 Opportunity
30 IMA402 Opportunity All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast; EU5: France, Germany, Italy, Spain, United Kingdom; sqNSCLC: squamous non - small - cell lung cancer; 1L Solid Tumors ~145k addressable P
Slide 31: TCER IMA402 Targeting PRAME Summary: Phase 1 Dose Escalation Study
C a nc er Cell TCER® IMA402 Targeting PRAME Summary: Phase 1 Dose Escalation Study 31 Dose escalation with higher DLs ongoing to leverage PRAME potential in advanced stage indications Tolerability Favorable tolerability profile Most common treatment - related AEs are low - grade CRS and transient ly
Slide 32: Phase 1/2 Clinical Trial to Evaluate TCER IMA402
Phase 1/2 Clinical Trial to Evaluate TCER® IMA402 Targeting PRAME 32 I MA4 0 2 1 Cutaneous melanoma, uveal melanoma, synovial sarcoma, endometrial cancer, ovarian cancer, squamous non - small cell lung cancer; 2 Step dosing introduced at DL4; Low - dose dexamethasone used as preventive measure for i
Slide 33: IMA402 Demonstrates Favorable Tolerability in N=33 Patients
33 IMA402 Demonstrates Favorable Tolerability in N=33 Patients Most Frequent Related AEs were Lymphopenia and CRS ≥ Grade 3 All Grades TEAEs, n [%] 17 [52] 33 [100] Any 15 [45] 32 [97] Treatment - related ≥ Grade 3 All Grades Treatment - related AEs 1 , n [%] 10 [30] 17 [52] Lymphopenia 1 [3] 16 [48
Slide 34: Early Signs of Clinical Activity Associated with PRAME Expression and IMA402 Dose
Positive/NT Negative PRAME Status 7+ * 1 - 6 Across DLs Dose Levels 78% 25% 14% Patients with Tumor Shrinkage Early Signs of Clinical Activity Associated with PRAME Expression and IMA402 Dose 34 BOR (RECIST 1.1) Ongoing response / SD (RECIST1.1/ iRECIST) Data cut - off Nov 6, 2024 * Patients who rec
Slide 35: Exemplary Patient Cases Suggesting Dose-Dependent Tumor Response
Exemplary Patient Cases Suggesting Dose - Dependent Tumor Response 35 Data cut - off Nov 6, 2024 BOR: Best Overall Response; SD: Stable Disease; cPR: Confirmed Partial Response; arrow: Ongoing response / stable disease (RECIST 1.1/ iRECIST) Patients with Disease Control (RECIST1.1) at Relevant Doses
Slide 36: TCER IMA401 - Off-the-Shelf TCR Bispecific Targeting MAGEA4/8
TCER® IMA401 - Off - the - Shelf TCR Bispecific Targeting MAGEA4/8 36
Slide 37: The IMA401 Commercial Opportunity in Solid Cancers
The IMA401 Commercial Opportunity in Solid Cancers TCER® IMA401 Targeting MAGEA4/8 37 IMA401 Opportunity 1L Solid Tumors All patient numbers refer to MAGEA4/8 + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast; EU5: France, Germany, Italy, Spain,
Slide 38: TCER IMA401 Targeting MAGEA4/8 Summary: Phase 1 Dose Escalation Study
C a nc er Cell MAGEA4/8 TCER® IMA401 Targeting MAGEA4/8 Summary: Phase 1 Dose Escalation Study 38 AE: Adverse Event; CRS: Cytokine Release Syndrome; (c)ORR: (confirmed) objective response rate; PR: Partial Response; DCR: disease control rate; CPI: checkpoint inhibitors; q4w: once every four weeks; H
Slide 39: Trial Design – IMA401-101 Phase 1a Dose Escalation
39 180 µg 540 µg 1800 µg 2500 µg Key Eligibility Criteria Object iv es Primary: • Determine MTD and/or RP2D Secondary: • Tolerability • Pharmacokinetics • Initial anti - tumor activity • Recurrent and/or refractory solid tumors • HLA - A*02:01 positive • MAGEA4/8 - positive as confirmed by mRNA - b
Slide 40: IMA401 Demonstrates Manageable Tolerability in N=35 Patients
40 IMA401 Demonstrates Manageable Tolerability in N=35 Patients Most Frequent Related AEs were Lymphopenia, CRS and Neutropenia ≥ Grade 3 All Grades TEAEs, n [%] 26 [74] 32 [91] Any 19 [54] 28 [80] Treatment - related ≥ Grade 3 All Grades Treatment - related AEs 1 , n [%] 11 [31] 12 [34] Lymphopenia
Slide 41: Objective Responses are Associated with Target Expression
1 Patients in this analysis had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression above indicated MAGEA4/A8 high qPCR threshold (n=17); PD: Progressive disease; PR: Partial response; cPR: confirmed Partial response; SD: Stable disease. Objective Responses are Associated with T
Slide 42: IMA401 Demonstrates Initial Anti-Tumor Activity in Multiple Tumor Types
IMA401 Demonstrates Initial Anti - Tumor Activity in Multiple Tumor Types 42 * Patients in this analysis are part of the efficacy analysis set with at least one post - treatment tumor assessment and had received IMA401 infusions at ≥1 mg and showed MAGEA4/8 target expression higher than the MAGEA4/8
Slide 43: The Immatics Opportunity
8o@ Immatics The Immatics Opportunity
Slide 44: The Immatics Opportunity
The Immatics Opportunity Delivering the Power of T Cells to Cancer Patients 44 Leveraging 2 TCR modalities to target solid cancers TCR - T cell therapy (ACTengine®) and TCR Bispecifics (TCER®) directed against pHLA targets to address late - stage and early - stage solid cancers Achieving robust cell
Slide 45: Thank you
Deli v ering the Power of T cells to Cancer Patients © Immatics. Not for further reproduction or distribution. Thank you www.immatics.com